A Phase I Study of the Safety and Immunogenicity of PENNVAX-G DNA (ENV & GAG) Administered by Intramuscular Biojector 2000 or CELLECTRA Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 ENV/CM240 GAG/POL) Boost in Healthy, HIV Uninfected Adults.

Trial Profile

A Phase I Study of the Safety and Immunogenicity of PENNVAX-G DNA (ENV & GAG) Administered by Intramuscular Biojector 2000 or CELLECTRA Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 ENV/CM240 GAG/POL) Boost in Healthy, HIV Uninfected Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs HIV clades A C D DNA vaccine Inovio (Primary) ; MVA HIV vaccine
  • Indications HIV infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Most Recent Events

    • 02 Sep 2017 Results published in the Journal of Infectious Diseases
    • 26 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.
    • 08 Apr 2013 Planned end date (Dec 2013) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top